Skip to content
value.today

Coya Therapeutics, Inc.

🇺🇸 Houston, Texas, USABiotechnologyFounded 2020
Total raised
$20 M
2 rounds on record
Latest round
$10 M
Apr 2022
First round on record
Dec 2020
Today
Went public
See the company page

Coya Therapeutics, Inc. is listed today as Coya Therapeutics, Inc.: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.

Funding rounds of Coya Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2024$10 MPrivate placement after listing$10 to $50 million

Coya Therapeutics, Inc.: Private sale, Oct 2024

Investors in this round

9 investors had bought by the notice of Oct 28, 2024: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Snyder · Executive Officer
  • Fred Grossman · Executive Officer
  • Howard Berman · Executive Officer, Director
  • Anabella Villalobos · Director
  • Ann Lee · Director
  • Arun Swaminathan · Director
  • Dieter Weinand · Director
  • Dov Goldstein · Director
  • Hideki Garren · Director
  • Wilbur Ross · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Wilmington Capital Securities, LLC (CRD 000133839) · Garden City,, New YorkSold in all US states
  • Chardan Capital Markets LLC (CRD 000120128) · New York, New YorkSold in all US states
  • BTIG, LLC (CRD 000122225) · San Francisco, CaliforniaSold in all US states

Remarks in the notice

  • On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”

Signed by Howard Berman, Chief Executive Officer. Source: SEC Form D, newest notice filed Oct 28, 2024. Read the notice at the SEC.

equitySEC
Dec 2023$26 MPrivate placement after listing$10 to $50 million

Coya Therapeutics, Inc.: Private sale, Dec 2023

Investors in this round

122 investors had bought by the notice of Dec 20, 2023: 122 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$26 M of $26 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • David Snyder · Executive Officer
  • Fred Grossman · Executive Officer
  • Howard Berman · Executive Officer, Director
  • Anabella Villalobos · Director
  • Ann Lee · Director
  • Dieter Weinand · Director
  • Dov Goldstein · Director
  • Hideki Garren · Director
  • Wilbur Ross · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • BTIG, LLC (CRD 122225) · San Francisco, CaliforniaSold in all US states
  • Newbridge Securities Corporation (CRD 104065) · Boca Raton, FloridaSold in all US states

Remarks in the notice

  • On fees: “The Company paid BTIG and Newbridge a fee based on gross proceeds from the sale of securities placed by each placement agent respectively and issued to Newbridge a warrant exercisable for 196,168 shares of Common Stock.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3.”

Signed by Howard Berman, Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2023. Read the notice at the SEC.

equity, optionsSEC
Apr 2022$10 MNo. 2$10 to $50 million

Coya Therapeutics, Inc.: Raise no. 2, Apr 2022

Investors in this round

45 investors had bought by the notice of May 20, 2022: 45 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $20 M offered; $10 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$1,400,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Adrian Hepner · Executive Officer
  • David Snyder · Executive Officer
  • Greg MacMichael · Executive Officer
  • Howard Berman · Executive Officer, Director
  • Anabella Villalobos · Director
  • Ann Lee · Director
  • Dov Goldstein · Director
  • Hideki Garren · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Wilmington Capital Securities, LLC (CRD 133839) · Garden City, New YorkSold in AL, AZ, CA, CO, CT, FL, GA, IL, IN, MA, MD, MI, MN, MO, NC, NH, NV, OH, PA, TN, TX, VA, WV, and outside the US

Remarks in the notice

  • On fees: “Assumes maximum commissions earned. Excludes value of warrants to purchase shares of common stock in an amount equal to 7% of the aggregate number of shares of equity securities ultimately issued upon conversion of the notes.”
  • On the use of proceeds: “Some of the proceeds may be used for working capital and general corporate purposes, including the payment of salaries and other fees to those listed in Item 3”

Signed by Howard Berman, Ceo. Source: SEC Form D, newest notice filed May 20, 2022. Read the notice at the SEC.

debt, optionsSEC
Dec 2020$10 MNo. 1$10 to $50 million

Coya Therapeutics, Inc.: Raise no. 1, Dec 2020

Investors in this round

57 investors had bought by the notice of Jan 5, 2021: 57 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$10 M of $10 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$700,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Andrea Goldstein · Executive Officer, Director
  • Howard Berman · Executive Officer, Director
  • Jani Tuomi · Director
  • Shawn M. Titcomb · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Tribal Capital Markets, LLC (CRD 38901) · broker-dealer Shawn M. Titcomb (CRD 2596352) · Sarasota, FloridaSold in AL, AZ, CA, FL, IL, KY, MD, MI, NJ, NY, OH, TX, and outside the US

Remarks in the notice

  • On fees: “In addition to the sales commissions, a warrant to purchase 525,049 shares of the issuer's common stock at a price per share of $1.606 was issued.”

Signed by Frances Dea, Attorney-in-Fact. Source: SEC Form D, newest notice filed Jan 5, 2021. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Coya Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Oct 2024).

    SEC Form D · Oct 2024

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2024

That is all the official record says: Coya Therapeutics, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Coya Therapeutics, Inc. are on record.

Investors#

No investor of Coya Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 57 investors.

Largest shareholders today

Institutions holding Coya Therapeutics, Inc. shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Coya Therapeutics, Inc.
NameRoleNamed in
David SnyderExecutive officerOct 2024
Fred GrossmanExecutive officerOct 2024
Howard BermanExecutive officerOct 2024
Adrian HepnerExecutive officerMay 2022
Greg MacMichaelExecutive officerMay 2022
Andrea GoldsteinExecutive officerJan 2021
Anabella VillalobosDirectorOct 2024
Ann LeeDirectorOct 2024
Arun SwaminathanDirectorOct 2024
Dieter WeinandDirectorOct 2024
Dov GoldsteinDirectorOct 2024
Hideki GarrenDirectorOct 2024
Howard BermanDirectorOct 2024
Wilbur RossDirectorOct 2024
Andrea GoldsteinDirectorJan 2021
Jani TuomiDirectorJan 2021
Shawn M. TitcombDirectorJan 2021

Went public since 2022. Its SEC number is that of a company listed on a stock exchange.